How to optimize current treatment of genotype 2 hepatitis C virus infection
The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatmen...
Gespeichert in:
| Veröffentlicht in: | Liver international 2014-02, Vol.34 (s1), p.13-17 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | s1 |
| container_start_page | 13 |
| container_title | Liver international |
| container_volume | 34 |
| creator | Marciano, Sebastián Gadano, Adrián C. |
| description | The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis. |
| doi_str_mv | 10.1111/liv.12399 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1496893862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490753070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0E4lFY8APIS1iE-pE48RJVvESBTYGl5aZjMCRxsB1K-XoChe6QmM2MNGeuNAehfUqOaV_Dyr4dU8alXEPbNM2LhDNO11cz41toJ4RnQqiUGd1EWyzlOSc530ZXF26Oo8Oujba2H4DLzntoIo4edKy_JmfwIzQuLlrADD9Bq6ONNuARfrO-C9g2BspoXbOLNoyuAuz99AG6OzudjC6S8e355ehknJRcCplMuSkKLRkwIWgKmqRATKZNWvYLxsSMSSNn03SWT4UuIS0zojMjwPTfSC0LPkCHy9zWu9cOQlS1DSVUlW7AdUHRVIpC8kKw_6Akz3oVpEePlmjpXQgejGq9rbVfKErUl2bVa1bfmnv24Ce2m9YwW5G_XntguATmtoLF30lqfHn_G5ksL2yI8L660P5FiZznmXq4OVfXk4nMr264euCf7IqV7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490753070</pqid></control><display><type>article</type><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Marciano, Sebastián ; Gadano, Adrián C.</creator><creatorcontrib>Marciano, Sebastián ; Gadano, Adrián C.</creatorcontrib><description>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12399</identifier><identifier>PMID: 24373073</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Algorithms ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; cirrhosis ; direct antiviral agents ; Drug Therapy, Combination - methods ; Drug Therapy, Combination - standards ; Genotype ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C - drug therapy ; Hepatitis C virus ; Humans ; Interferon-alpha - therapeutic use ; pegylated interferon ; Polyethylene Glycols - therapeutic use ; predictors of treatment response ; Recombinant Proteins - therapeutic use ; ribavirin ; Ribavirin - therapeutic use ; Standard of Care - trends ; Time Factors ; treatment duration ; Treatment Outcome</subject><ispartof>Liver international, 2014-02, Vol.34 (s1), p.13-17</ispartof><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</citedby><cites>FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12399$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12399$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24373073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marciano, Sebastián</creatorcontrib><creatorcontrib>Gadano, Adrián C.</creatorcontrib><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</description><subject>Algorithms</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>cirrhosis</subject><subject>direct antiviral agents</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug Therapy, Combination - standards</subject><subject>Genotype</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C virus</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>pegylated interferon</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>predictors of treatment response</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Standard of Care - trends</subject><subject>Time Factors</subject><subject>treatment duration</subject><subject>Treatment Outcome</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0E4lFY8APIS1iE-pE48RJVvESBTYGl5aZjMCRxsB1K-XoChe6QmM2MNGeuNAehfUqOaV_Dyr4dU8alXEPbNM2LhDNO11cz41toJ4RnQqiUGd1EWyzlOSc530ZXF26Oo8Oujba2H4DLzntoIo4edKy_JmfwIzQuLlrADD9Bq6ONNuARfrO-C9g2BspoXbOLNoyuAuz99AG6OzudjC6S8e355ehknJRcCplMuSkKLRkwIWgKmqRATKZNWvYLxsSMSSNn03SWT4UuIS0zojMjwPTfSC0LPkCHy9zWu9cOQlS1DSVUlW7AdUHRVIpC8kKw_6Akz3oVpEePlmjpXQgejGq9rbVfKErUl2bVa1bfmnv24Ce2m9YwW5G_XntguATmtoLF30lqfHn_G5ksL2yI8L660P5FiZznmXq4OVfXk4nMr264euCf7IqV7g</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Marciano, Sebastián</creator><creator>Gadano, Adrián C.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201402</creationdate><title>How to optimize current treatment of genotype 2 hepatitis C virus infection</title><author>Marciano, Sebastián ; Gadano, Adrián C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3969-b3f88a92e26614ea04e0f5af4c3f8226d29f9db4d7b6ace4c50a5f6ef4789a983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Algorithms</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>cirrhosis</topic><topic>direct antiviral agents</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug Therapy, Combination - standards</topic><topic>Genotype</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C virus</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>pegylated interferon</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>predictors of treatment response</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Standard of Care - trends</topic><topic>Time Factors</topic><topic>treatment duration</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marciano, Sebastián</creatorcontrib><creatorcontrib>Gadano, Adrián C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marciano, Sebastián</au><au>Gadano, Adrián C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How to optimize current treatment of genotype 2 hepatitis C virus infection</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2014-02</date><risdate>2014</risdate><volume>34</volume><issue>s1</issue><spage>13</spage><epage>17</epage><pages>13-17</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24373073</pmid><doi>10.1111/liv.12399</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2014-02, Vol.34 (s1), p.13-17 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1496893862 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | Algorithms Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use cirrhosis direct antiviral agents Drug Therapy, Combination - methods Drug Therapy, Combination - standards Genotype Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C - drug therapy Hepatitis C virus Humans Interferon-alpha - therapeutic use pegylated interferon Polyethylene Glycols - therapeutic use predictors of treatment response Recombinant Proteins - therapeutic use ribavirin Ribavirin - therapeutic use Standard of Care - trends Time Factors treatment duration Treatment Outcome |
| title | How to optimize current treatment of genotype 2 hepatitis C virus infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-06T17%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20to%20optimize%20current%20treatment%20of%20genotype%202%20hepatitis%20C%20virus%20infection&rft.jtitle=Liver%20international&rft.au=Marciano,%20Sebasti%C3%A1n&rft.date=2014-02&rft.volume=34&rft.issue=s1&rft.spage=13&rft.epage=17&rft.pages=13-17&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12399&rft_dat=%3Cproquest_cross%3E1490753070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490753070&rft_id=info:pmid/24373073&rfr_iscdi=true |